Medical Fund in Poland – IDA report

Due to the Act on the Medical Fund in force we looked into registration drugs in European Medicines Agency (EMA) to see which products may be included in the upcoming high clinical value drugs list by AOTMiT.  

From 2017 to the end of July 2021, 268 new products were registered by EMA, 107 of which are orphan drugs (40%). Around 88% of these drugs may be assessed by AOTMiT, rest of them – 12% are already being reimbursed in Poland. Out of these 88% drugs – 44 are oncological drugs (including 18 oncological orphan drugs (41%)), and 191 non-oncological drugs (including 48 non-oncological orphan drugs (25%)). 

According to the ATC classification, the largest group of drugs (TOP 3) are antineoplastic and immunomodulating agents (ATC: L, 59 products), antiinfectives for systemic use (ATC: J, 36 products) and nervous system drugs (ATC N, 30 products). 

More in out IDA report.